Diagnostic marker for hepatocellular carcinoma and application thereof

By using the fibrinogen alpha subunit encoding gene FGA as a diagnostic marker for hepatocellular carcinoma, the problem of low early diagnosis sensitivity of hepatocellular carcinoma in the prior art is solved, and higher diagnostic efficiency and accuracy are achieved. The diagnosis of FGA is achieved. The rate is significantly higher than that of AFP.

CN119023972APending Publication Date: 2024-11-26THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411210040.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has low sensitivity in the early diagnosis of hepatocellular carcinoma, and the diagnostic efficacy of AFP markers on small hepatocellular carcinoma or early hepatocellular carcinoma is insufficient, resulting in the best period of treatment often missed.

Method used

FGA, a fibrinogen α subunit encoding gene, was used as a diagnostic marker for hepatocellular carcinoma, and the FGA expression difference between hepatocellular carcinoma tissue and adjacent tissue was detected in plasma, and the diagnosis was determined by combining ROC analysis and cutoff value. standard.

Benefits of technology

The diagnosis rate of hepatocellular carcinoma was improved, and the diagnosis rate of FGA reached 82.9%, which was significantly higher than 70% of AFP. The detection rate of hepatocellular carcinoma was improved under AFP negative condition and enhanced diagnostic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023972A_ABST
    Figure CN119023972A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of hepatocellular carcinoma diagnosis, and particularly discloses a hepatocellular carcinoma diagnostic marker and application thereof.The hepatocellular carcinoma diagnostic marker is FGA, the FGA gene encodes an alpha subunit of blood coagulation factor fibrinogen, the fibrinogen is a constituent part of blood clots, the FGA is applied to detection of hepatocellular carcinoma, and the FGA gene can be used for detecting hepatocellular carcinoma. According to the application, the FGA expression in hepatocellular carcinoma tissues is lower than that in para-carcinoma tissues, the FGA expression in the plasma of a hepatocellular carcinoma patient is higher than that in normal healthy people, the FGA expression of the hepatocellular carcinoma postoperative patient is obviously reduced, and meanwhile, when the result of AFP diagnosis on the hepatocellular carcinoma patient is negative, the probability that the FGA in the plasma diagnoses the hepatocellular carcinoma patient to be positive reaches 75%, and the FGA expression in the hepatocellular carcinoma postoperative patient is obviously reduced. Therefore, the plasma FGA can obviously improve the detection rate of the AFP negative hepatocellular carcinoma, and the diagnosis efficiency of the hepatocellular carcinoma is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of hepatocellular carcinoma diagnosis, and in particular relates to a hepatocellular carcinoma diagnosis marker and application thereof. Background Art

[0002] Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in my country and even in the world. In recent years, with the continuous advancement of surgical techniques, comprehensive treatment methods mainly based on "surgical treatment" have been widely used in clinic, which has significantly improved the overall treatment effect of HCC.

[0003] However, the overall treatment effect is still poor, and there is a high recurrence and metastasis rate after surgery. The main reason is that it is impossible to provide timely and effective treatment for patients with hepatocellular carcinoma. 60-70% of hepatocellular carcinoma patients have entered the middle and late stages when they seek medical treatment, thus missing the best time for treatment. Therefore, effective early diagnosis is of great significance to patients with hepatocellular carcinoma.

[0004] Currently, only a few tumor markers such as AFP are widely recognized and used in the diagnosis and treatment of hepatocellular carcinoma in clinical practice. Despite this, these tumor biomarkers still have certain limitations. Studies have reported that there is no significant increase in some patients with small hepatocellular carcinoma or early hepatocellular carcinoma, and the sensitivity of early hepatocellular carcinoma diagnosis is only 20-40%.

[0005] Therefore, actively searching for diagnostic indicators with excellent sensitivity and specificity for diagnosing HCC alone, or combining with AFP to improve the diagnostic efficacy of HCC, will be of great clinical value. Summary of the invention

[0006] The purpose of the present invention is to provide a diagnostic marker for hepatocellular carcinoma and its application to solve the problems raised in the above background technology.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] A diagnostic marker for hepatocellular carcinoma and its application. The diagnostic marker for hepatocellular carcinoma is FGA. The FGA gene encodes the alpha subunit of the coagulation factor fibrinogen, which is a component of blood clots.

[0009] Preferably, the FGA is applied in the detection of hepatocellular carcinoma.

[0010] Compared with the prior art, the present invention has the following beneficial effects:

[0011] The present invention finds that the expression of FGA in hepatocellular carcinoma tissue is lower than that in adjacent tissue, the expression of FGA in the plasma of liver cancer patients is higher than that in normal healthy people, and the expression of FGA in patients after liver cancer surgery is significantly decreased. At the same time, ROC analysis shows that the area under the curve (AUC) of FGA is 0.911, and its diagnostic efficacy is slightly better than AFP. The FGA cutoff value (cutoff value) was calculated by the Youden index method and determined to be 582.49ng / ml. Using this value as the boundary, hepatocellular carcinoma patients are divided into an FGA positive expression group and an FGA negative expression group; similarly, according to the clinical normal value range of AFP, its cutoff value is determined to be 8.37ng / ml, and this value is also used as the boundary to divide hepatocellular carcinoma patients into an AFP positive expression group and an AFP negative expression group. After the experiment, the present invention found that the diagnostic rate of FGA was 82.9%, which is higher than 70% of AFP. The present invention analyzes that when AFP diagnoses hepatocellular carcinoma patients as negative, the probability of FGA in plasma diagnosing it as positive reaches 75%, which shows that plasma FGA can significantly improve the detection rate of AFP-negative hepatocellular carcinoma and increase the diagnostic efficacy of hepatocellular carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Schematic diagram of the expression of FGA in cancer and paracancerous cells, the expression of FGA in HCC cells and normal cells, and the analysis of overexpression of FGA inhibiting EMT of HCC cells in the present invention;

[0013] Figure 2 Schematic diagram of the standard protein fitting curve of plasma FGA in the present invention;

[0014] Figure 3 Schematic diagram of the expression level of plasma FGA in the normal population and the plasma of hepatocellular carcinoma patients in the present invention;

[0015] Figure 4 Schematic diagram of the expression of FGA in the plasma of patients with hepatocellular carcinoma before and after surgery in the present invention;

[0016] Figure 5 Schematic diagram of the receiver operating characteristic curve for independent diagnosis of hepatocellular carcinoma by plasma FGA and AFP in the present invention;

[0017] Figure 6 A schematic diagram of the proportion of FGA-positive and AFP-positive hepatocellular carcinoma patients in the present invention;

[0018] Figure 7 Schematic diagram of the proportion of plasma FGA-positive hepatocellular carcinoma patients among AFP-positive and AFP-negative hepatocellular carcinoma patients in the present invention;

[0019] Figure 8 Schematic diagram of the correlation between AFP and FGA in the present invention. DETAILED DESCRIPTION

[0020] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0021] See also Figure 1 - Figure 8 As shown, a diagnostic marker for hepatocellular carcinoma and its application, FGA (fibrinogen alpha chai n), the gene encodes the α subunit of the coagulation factor fibrinogen, which is a component of blood clots.

[0022] FGA gene, alias: F ib2, gene ID: 2243, chromosome location: According to the GRCh37 version of the human genome, the FGA gene is located on the long arm of chromosome 4 (4q28)

[0023] The FGA gene encodes the α subunit of fibrinogen, which is a glycoprotein composed of three pairs of different polypeptide chains (α, β, γ). After the blood vessel is damaged, the coagulation system is activated, and fibrinogen is hydrolyzed into fibrin monomers under the action of thrombin. These monomers are further cross-linked to form water-insoluble fibrin polymers, which are the main components of blood clots. This process is a key step in hemostasis and thrombosis.

[0024] After vascular injury, the encoded proproprotein is proteolytically processed by thrombin during the conversion of fibrinogen to fibrin. Mutations in this gene can lead to a variety of diseases, including dysfibrinogenemia, hypofibrinogenemia, afibrinogenemia, and renal amyloidosis.

[0025] Experimental design:

[0026] To explore the expression difference of FGA (fibrinogen α chain) in cancer tissue and adjacent paracancerous tissue, and analyze its relationship with β-acti n expression.

[0027] Experimental Materials

[0028] Cancer tissue and adjacent tissue samples (from four patients: Patient 1 to Patient 4).

[0029] Reagents and supplies for immunoblotting (IB). Specific antibodies for FGA and β-actin.

[0030] Protein extraction and quantification reagents. Common laboratory equipment (such as centrifuge, electrophoresis instrument, membrane transfer instrument, etc.).

[0031] Experimental procedures

[0032] Sample preparation:

[0033] Cancer tissue and adjacent tissue samples were obtained from four patients (Patient 1 to Patient 4).

[0034] The samples were processed appropriately and total protein was extracted.

[0035] Protein quantification:

[0036] The extracted proteins were quantified using a protein quantification reagent to ensure that the protein concentration of each sample was consistent.

[0037] Immunoblotting (IB):

[0038] The quantified protein samples were subjected to electrophoresis to separate proteins of different sizes.

[0039] The proteins after electrophoresis were transferred to a membrane and subjected to immunoblotting.

[0040] The proteins on the membrane were incubated and detected using specific antibodies against FGA and β-actin, respectively.

[0041] Result analysis:

[0042] Observe and record the protein expression of FGA and β-actin in each sample.

[0043] The expression of FGA in cancer tissues and adjacent paracancerous tissues was compared.

[0044] The expression relationship between FGA and β-actin was analyzed.

[0045] from Figure 1 As can be seen in A, the expression of FGA in cancer and adjacent tissues, and the differences in the expression of FGA and β-actin between different patients, can be seen from the figure that the expression of FGA in hepatocellular carcinoma tissue is lower than that in adjacent tissues.

[0046] It is expected that the expression level of β-actin as an internal reference protein in cancer tissues and adjacent tissues is relatively stable.

[0047] Experimental Design 2:

[0048] Total proteins were extracted from three cell lines (HepG2, Hep3B, LO2).

[0049] Protein quantification: Quantify the extracted protein using a BCA protein quantification kit or similar method to ensure that the total amount of protein in each sample is consistent when loaded.

[0050] SDS-PAGE electrophoresis: Mix the quantified protein sample with SDS loading buffer, heat denature it and load it onto SDS-PAGE gel.

[0051] Electrophoresis is performed to separate proteins according to their molecular weight.

[0052] Membrane transfer: Transfer the proteins on the gel after electrophoresis to PVDF membrane or nitrocellulose membrane.

[0053] Blocking: Block the membrane with 5% skim milk or BSA to reduce nonspecific binding.

[0054] Antibody incubation: The membrane was incubated with specific primary antibodies against FGA and β-actin, respectively.

[0055] After washing, incubation is performed using a corresponding secondary antibody (such as an HRP-labeled secondary antibody).

[0056] Color development: Use a color development system such as ECL (enhanced chemiluminescence) to develop the membrane to form visible bands.

[0057] Depend on Figure 2 It can be seen that the expression of FGA in liver cancer cells is higher than that in normal healthy people.

[0058] Design experiment 3:

[0059] 1. Experimental Preparation

[0060] Cell culture: Ensure that HCC cell lines (such as HepG2 or Hep3B) are grown to the logarithmic phase under appropriate culture conditions, and prepare cells overexpressing FGA as experimental groups, as well as untreated cells or cells transfected with an empty vector as controls.

[0061] Transfection: Use an appropriate transfection reagent (such as Lipofectamine) to transfect the FGA expression plasmid into HCC cells to achieve overexpression of FGA. Follow the instructions of the transfection reagent to ensure transfection efficiency.

[0062] Collect cells: At an appropriate time point after transfection (e.g., 24-48 hours), collect cells for subsequent experiments. Digest the cells with trypsin and collect the cell pellet by centrifugation.

[0063] 2. Sample preparation

[0064] Cell lysis: Add an appropriate amount of lysis buffer (such as RIPA buffer) to the collected cell pellet, and add protease inhibitors and phosphatase inhibitors to prevent protein degradation. The cells are fully lysed by ultrasonic disruption or mechanical homogenization. Protein quantification: Quantify the protein in the lysate using the BCA method or other protein quantification methods to ensure that each sample contains an equal amount of protein when loaded.

[0065] 3. SDS-PAGE electrophoresis

[0066] Gel preparation: Select the appropriate separation gel concentration (such as 8%-12%) according to the experimental needs, prepare the separation gel and the concentrated gel, and pour them into the vertical electrophoresis tank. Sample loading: Mix the quantified protein sample with the loading buffer, boil and denature it, and use a microinjector to add the sample to the loading hole of the electrophoresis tank. Electrophoresis: Perform electrophoresis at an appropriate voltage to separate the protein sample in the gel according to its molecular weight.

[0067] 4. Transfer

[0068] Prepare membrane and filter paper: Cut the PVDF membrane or nitrocellulose membrane and filter paper of appropriate size, and make sure the size of the membrane and filter paper matches the gel. Transfer: Use wet transfer or semi-dry transfer to transfer the protein on the gel to the membrane. During the transfer process, make sure there are no bubbles between the membrane and the gel, and maintain the appropriate current or voltage for transfer.

[0069] 5. Immune Response

[0070] Blocking: Place the transferred membrane in a container containing blocking solution (such as 5% skim milk or BSA) and block on a shaker at room temperature for 1-2 hours to reduce nonspecific binding. Primary antibody incubation: Select appropriate EMT-related antibodies (such as E-cadher in, N-cadher in, Viment in, etc.) and FGA antibodies according to experimental needs, and incubate the membrane with the diluted primary antibody solution at 4°C overnight or at room temperature for 1-2 hours. Washing: Wash the membrane 3 times with TBST or PBS buffer for 5-10 minutes each time to remove unbound primary antibodies. Secondary antibody incubation: Incubate the membrane with diluted secondary antibody solution (usually an antibody from a species different from the primary antibody and labeled with HRP, etc.) at room temperature for 1-2 hours. Wash again: Wash the membrane again with TBST or PBS buffer 3 times for 5-10 minutes each time to remove unbound secondary antibodies.

[0071] 6. Signal Detection

[0072] Color development: Use ECL or other chemiluminescent reagents to develop the membrane so that the protein bands on the membrane can be seen on X-ray film or chemiluminescent imaging system.

[0073] Exposure and imaging: Place the membrane in an exposure box, contact it with an X-ray film or chemiluminescence imaging system, and adjust the exposure time according to the strength of the signal to obtain a clear image.

[0074] Depend on Figure 1 The FGA protein expression levels presented in C and D are relatively clear.

[0075] Use FGA standards of known concentrations to perform immunoblotting (IB) or other immunoassays (such as ELISA) on FGA standards of different concentrations, using antibodies specific to FGA for detection. Record the signal intensity value corresponding to each standard concentration. Figure 2 The curve in .

[0076] Figure 3 The expression levels of plasma FGA (fibrinogen) differ between normal people and hepatocellular carcinoma (HCC) patients. The average plasma FGA level of normal healthy people is about 500ng / mL, while the level of HCC patients is significantly increased, reaching an average of about 1500ng / mL. This significant difference indicates that plasma FGA levels can be used as an important biomarker to distinguish normal people from HCC patients. Abnormal liver function in HCC patients may affect the synthesis or degradation process of fibrinogen, resulting in an increase in its concentration in plasma. Therefore, monitoring plasma FGA levels is of great significance for the early diagnosis, disease monitoring and prognosis evaluation of hepatocellular carcinoma.

[0077] Figure 4 The expression changes of FGA (fibrinogen) in plasma after surgery. The FGA level before surgery (red column) was as high as 1500ng / ml, while it dropped significantly to 1000ng / ml after surgery (blue column), indicating that surgery had a significant effect on the expression of FGA. Detection methods include, but are not limited to, enzyme-linked immunosorbent assay, radioimmunoassay (RIA), immunoturbidimetry and other immunological detection methods to determine the concentration of FGA in plasma.

[0078] Figure 5 Receiver operating characteristic (ROC) curve of plasma FGA and AFP in the independent diagnosis of hepatocellular carcinoma (HCC). The ROC curve is an important tool to measure the accuracy and reliability of diagnostic tests, where the horizontal axis represents 1-specificity (false positive rate) and the vertical axis represents sensitivity (true positive rate).

[0079] It can be observed from the figure that the ROC curve of AFP (usually marked in red or higher position) shows a higher area under the curve (AUC) of 0.911, indicating that AFP has higher accuracy and reliability in diagnosing hepatocellular carcinoma. In contrast, the AUC of the ROC curve of FGA (usually marked in blue or lower position) is 0.859, which also shows good diagnostic value.

[0080]

[0081] Figure 6 The different proportions of FGA-positive and AFP-positive patients in hepatocellular carcinoma (HCC) were revealed in the study. Specifically, 82.9% of patients were FGA-positive, while 70% were AFP-positive. This data comparison shows that in HCC patients, the positivity rate of FGA is significantly higher than that of AFP. Therefore, it can be considered that FGA, as a tumor marker, may show higher sensitivity and accuracy in the diagnosis of hepatocellular carcinoma. This means that FGA may be able to detect HCC earlier, or its test results are more reliable. In summary, FGA may be a more valuable indicator than AFP in the diagnosis of HCC.

[0082] Figure 7 The different proportions of plasma FGA (Fibr i nogen Al pha) positivity in AFP (Al pha-Fetoprophen)-positive and -negative hepatocellular carcinoma (HCC) patients. Specifically, in AFP-positive HCC patients, the proportion of FGA positivity was relatively low (about 28%), while in AFP-negative HCC patients, the proportion of FGA positivity increased significantly to about 90%. This comparison shows that FGA positivity has higher specificity in AFP-negative HCC patients and can be used as an important biomarker for such patients. For clinical purposes, this finding means that FGA testing may provide additional diagnostic value in suspected HCC cases with negative AFP tests, helping doctors more accurately identify cases that require special attention.

[0083] Figure 8The relationship between AFP (alpha-fetoprotein) levels and different health conditions (HCC patients and normal healthy people) is shown in the figure. The figure uses box plots and scatter plots to intuitively present the changing trends in health status indicators of different health groups as the AFP concentration increases. Red circles represent HCC patients, and blue triangles represent normal healthy people. The Spearman correlation coefficient is 0.567, and the P value is less than 0.001, indicating that there is a significant positive correlation between AFP levels and health conditions. Specifically, with the increase in AFP concentrations, the health status indicators of both groups of people showed an upward trend, but the changes in the indicators of HCC patients were more significant, showing a difference from the healthy population.

[0084] As the precision medicine industry continues to rise, more and more attention is paid to the application of biomarkers in precision medicine. It is not difficult to find that the current research on FGA is mainly focused on basic research such as molecular mechanisms, and its expression level in the plasma of hepatocellular carcinoma patients and its related translational research have not been reported.

[0085] The present invention finds that the expression of FGA in hepatocellular carcinoma tissue is lower than that in adjacent tissue, the expression of FGA in the plasma of liver cancer patients is higher than that in normal healthy people, and the expression of FGA in patients after liver cancer surgery is significantly decreased. At the same time, ROC analysis shows that the area under the curve (AUC) of FGA is 0.911, and its diagnostic efficacy is slightly better than AFP. The FGA cutoff value (cutoff value) was calculated by the Youden index method and determined to be 582.49 ng / ml. And with this value as the boundary, hepatocellular carcinoma patients are divided into FGA positive expression group and FGA negative expression group; similarly, according to the clinical normal value range of AFP, its cutoff value is determined to be 8.37 ng / ml, and with this value as the boundary, hepatocellular carcinoma patients are divided into AFP positive expression group and AFP negative expression group.

[0086] The diagnostic rate of FGA in 70 HCC patients was 82.9%, which is higher than 70% of AFP. The present invention analyzed that when AFP diagnosed hepatocellular carcinoma patients as negative, the probability of FGA in plasma diagnosing them as positive reached 75%, which shows that plasma FGA can significantly improve the detection rate of AFP-negative hepatocellular carcinoma and increase the diagnostic efficacy of hepatocellular carcinoma.

[0087] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A diagnostic marker for hepatocellular carcinoma, characterized in that The diagnostic marker for hepatocellular carcinoma is FGA, which is a gene that encodes the α subunit of the coagulation factor fibrinogen, which is a component of blood clots.

2. A diagnostic marker for hepatocellular carcinoma according to claim 1, characterized in that: The FGA is applied in the detection of hepatocellular carcinoma.

Citation Information

Cited By

  • Biomarker for diagnosing hepatocellular carcinoma and application thereof

    CN120829975A